Apotex Health stock
APTX.TOTSXApotex Health Corp., HealthcareISIN CA03772D1015
70Score 70 out of 100, Strong
Price and trend
71 / 100
Price history
+43% since 2026The chart shows daily closing prices since 10 Jun 2026, adjusted for stock splits and excluding dividends. Click into the chart to set a price alert at that price.
Overheated: the price has risen very quickly lately (RSI 89).
The price is 2.9% below its 52-week high. Largest decline since 10 Jun 2026: 23% (July 2026 to October 2026).
Chart figures for advanced users
- SMA 50$23.21
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$27.05
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)89
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$18.97
- The lowest closing price of the last twelve months.
- Resistance$27.87
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Apotex Health Corp. belongs to the Drug Manufacturers (Specialty & Generic) industry (Canada) and, with a market value of $6.18B, is number 39 of 78 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $2.45B (up 4.2% year on year) and earnings of $262.58M (up 146.4%).
- For fiscal 2026, analysts expect on average revenue of $2.39B (down 2.7%) and adjusted earnings per share of $1.27.
Show more
- MEQIRI Score 70 out of 100 (Strong): rank 131 of 714 in Healthcare, median 53.
- Our model puts fair value at $38.48, with the price 34% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Below fair valuePrice 34% below the fair value of $38.48.Valuation 76
- Analysts expect strong earnings growthUp 21.5% a year through 2029 (estimates from 7 analysts).Growth 50
- High return on capitalReturn on invested capital 19.6% in fiscal 2025, Drug Manufacturers (Specialty & Generic) median 11.3%.Profitability 74
Weaknesses
None of our weakness checks flags anything. Crash risk is measured separately.
Its standout strengths are momentum and fundamentals.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 71 to 70.
Fundamentals are strong, with strong cash generation.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk not measured
How well MEQIRI warnsFor stocks from Japan, China, Hong Kong, Taiwan, Korea, Canada, India and Brazil we only show crash risk once a separate backtest shows that it warns as well there as in the US and Europe.
Valuation
Valuation signal
Significantly undervaluedClosing price of 11 Nov 2026, used by the daily score.
In our model the price counts as cheap below $27.49 and expensive above $64.14 (uncertainty high, based on the price swings of the past year).
The two parts of the fair value come to $40.05 (cash-flow model) and $36.92 (industry comparison), and the gap between them shows how uncertain the estimate is. The price is below both.
Calculated with a cost of equity of 8.2%. At 9.2% the fair value would be $35.17, at 7.2% it would be $43.46.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (32.6).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In fiscal 2025, revenue rose 4.2% on the prior year. Revenue has grown solidly since 2023, at about 9% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 56%, operating 23%, net 11%.
Debt & balance sheet
latest quarterDebt is elevated. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 2 Dec 2026in 20 days
- Last reported
- 12 Nov 2026EPS reported $0.40 (expected $0.18)above expectations
Analyst estimates
Analysts have raised their 2027 earnings estimate by 4.4% since 25 Oct 2026.
- Earnings per share
- $1.27+4.4%
- Revenue
- $2.39B0.0%
- Earnings per share
- $1.62+2.0%
- Revenue
- $2.59B0.0%
MEQIRI has stored the estimates since 25 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
What happened at Apotex Health
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 70
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Drug Manufacturers (Specialty & Generic)
The next larger and next smaller companies by market value
- Huadong Medicine000963.SZ $6.98B62
- Alkem LaboratoriesALKEM.NS $6.95B65
- Lantheus HoldingsLNTH $6.64B76
- China Resources Sanjiu Medical & Pharmaceutical000999.SZ $6.25B73
- Gland PharmaGLAND.NS $5.75B70
- Sumitomo Pharma4506.T $5.45B57
- Ipca LaboratoriesIPCALAB.NS $5.25B70
- Shenzhen Salubris Pharmaceuticals002294.SZ $5.03B53
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Mar 2026
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 11 Nov 2026 ($1 = CA$1.4235)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong since 10 Nov 2026, previously Neutral
- Valuation signal Undervalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.